PLUR · Pluri Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.34M | $326.0K | $287.0K | $234.0K | - | $23.0K |
| Cost of Revenue | $682.0K | $4.0K | $9.0K | - | - | - |
| Gross Profit | $654.0K | $322.0K | $234.0K | - | - | $23.0K |
| R&D | $12.85M | $12.45M | $17.41M | $24.61M | $30.53M | $23.10M |
| SG&A | $9.98M | $10.03M | $11.78M | $17.45M | $20.56M | $7.92M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $253.0K | $253.0K | $362.0K | $1.05M | $1.37M | $1.57M |
| Operating Income | ($22.18M) | ($22.16M) | ($27.25M) | ($41.59M) | ($50.62M) | ($29.48M) |
| Interest Expense | $873.0K | $866.0K | $843.0K | $78.0K | - | - |
| Income Tax | ($5.0K) | - | - | - | - | - |
| Net Income | ($22.58M) | ($20.89M) | ($28.32M) | ($41.24M) | ($49.87M) | ($29.15M) |
| EPS - Basic | ($3.56) | ($3.99) | ($6.24) | ($14.16) | - | - |
| EPS - Diluted | ($3.56) | ($3.99) | ($6.24) | ($10.24) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.89M | $6.78M | $5.36M | $9.77M | $31.24M | $8.27M |
| Accounts Receivable | - | - | - | $3.0K | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $866.0K | $964.0K | $1.81M | $1.78M | $2.53M | $1.97M |
| Current Assets | $22.09M | $31.11M | $41.41M | $57.75M | $67.37M | $48.46M |
| Total Assets | $38.68M | $39.53M | $50.80M | $68.06M | $93.54M | $65.53M |
| Current Liabilities | $32.33M | $4.45M | $5.62M | $6.83M | $11.52M | $7.99M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | ($6.84M) | $96.0K | $13.36M | $30.04M | $57.15M | $56.10M |
| Retained Earnings | ($443.06M) | ($420.47M) | ($399.58M) | ($371.26M) | ($330.02M) | ($280.16M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($18.21M) | ($18.02M) | ($22.86M) | ($36.50M) | ($30.91M) | ($26.37M) |
| Investing Cash Flow | $8.03M | $10.58M | $9.70M | $11.78M | ($7.26M) | ($30.46M) |
| Financing Cash Flow | $9.53M | $8.84M | $8.02M | $7.50M | $61.40M | $60.87M |
| CapEx | $1.62M | $323.0K | $262.0K | $280.0K | $373.0K | $270.0K |
| Free Cash Flow | ($19.83M) | ($18.34M) | ($23.12M) | ($36.78M) | ($31.28M) | ($26.64M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 49.0% | 98.8% | 81.5% | - | - | 100.0% |
| Operating margin | -1659.9% | -6796.9% | -9493.4% | -17774.8% | - | -128156.5% |
| EBITDA margin | -1640.9% | -6719.3% | -9367.2% | -17324.8% | - | -121330.4% |
| Net margin | -1690.3% | -6407.4% | -9867.9% | -17624.8% | - | -126747.8% |
| Free cash flow margin | -1484.2% | -5627.0% | -8055.4% | -15718.4% | - | -115821.7% |
| FCF / Net income | 0.88 | 0.88 | 0.82 | 0.89 | 0.63 | 0.91 |
| R&D / Revenue | 961.9% | 3817.8% | 6067.2% | 10515.0% | - | 100417.4% |
| SG&A / Revenue | 746.9% | 3077.9% | 4104.2% | 7457.3% | - | 34443.5% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -58.4% | -52.8% | -55.8% | -60.6% | -53.3% | -44.5% |
| Return on equity | 330.1% | -21758.3% | -212.1% | -137.3% | -87.3% | -52.0% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.68 | 6.98 | 7.37 | 8.46 | 5.85 | 6.07 |
| Quick ratio | 0.68 | 6.98 | 7.37 | 8.46 | 5.85 | 6.07 |
| Cash ratio | 0.18 | 1.52 | 0.95 | 1.43 | 2.71 | 1.04 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -25.4x | -25.6x | -32.3x | -533.2x | - | - |
| Equity multiplier | -5.65 | 411.74 | 3.80 | 2.27 | 1.64 | 1.17 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.03 | 0.01 | 0.01 | 0.00 | - | 0.00 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | 5d | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | 463d | 87965d | 73487d | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | 315.5x | 15.4x | - | - | - |
| P / S | 23.5x | 92.9x | 717.9x | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 309.8% | 13.6% | 22.6% | - | - | -57.4% |
| Revenue CAGR (3y) | 78.7% | - | 131.9% | 63.0% | - | - |
| Revenue CAGR (5y) | 125.3% | 43.3% | 41.8% | - | - | -42.9% |
| Gross profit growth (YoY) | 103.1% | 37.6% | - | - | - | -55.8% |
| Operating income growth (YoY) | -0.1% | 18.7% | 34.5% | 17.8% | -71.7% | 17.0% |
| Net income growth (YoY) | -8.1% | 26.2% | 31.3% | 17.3% | -71.1% | 17.4% |
| EPS growth (YoY) | 10.8% | 36.1% | 39.1% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -8.1% | 20.7% | 37.1% | -17.6% | -17.4% | 10.3% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | -99.3% | -55.5% | -47.4% | 1.9% | 157.1% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Pluri Inc. against the 5 most active filers in the same SIC group.